Ratings Trulieve Cannabis Corp.

Equities

TRUL

CA89788C1041

Market Closed - Canadian Securities Exchange Other stock markets 03:59:44 2024-05-13 pm EDT			5-day change	1st Jan Change
16.35 ^CAD	+3.02%		+7.78%	+138.69%

May. 10	Trulieve to Open Medical Cannabis Dispensary in Stuart, Florida	CI
May. 09	Trulieve Cannabis' quarterly loss narrows on demand boost	RE

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company is in a robust financial situation considering its net cash and margin position.
The company has a low valuation given the cash flows generated by its activity.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
Low profitability weakens the company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TRULIEVE CANNABIS CORP.	+138.69%	2.18B		C
CURALEAF HOLDINGS, INC.	+39.02%	4.09B		C-
GOODNESS GROWTH HOLDINGS, INC.	+138.10%	76.48M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes